Latest Sarcoma Stories
A new analysis suggests patients and physicians should rethink the pros and cons of limb-sparing surgery versus amputation for bone and soft tissue sarcomas of the lower limb.
Limb-sparing surgery, which has been taking the place of amputation for bone and soft tissue sarcomas of the lower limb in recent years, may not provide much or even any additional benefit to patients according to a new review. The analysis, published in the September 15, 2009 issue of Cancer
The largest analysis of its kind has found that Caucasians are much more likely than people in other racial/ethnic groups to develop a rare bone and soft tissue cancer called Ewing's sarcoma.
A grant from the Liddy Shriver Sarcoma Initiative will allow Dr. Pulivarthi Rao, associate professor of pediatrics at Baylor College of Medicine, and his team of researchers to explore the role of the gene CDC5L in the development of osteosarcoma, the most common bone cancer in children.
SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body.
FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been approved...
NEW YORK, April 29 /PRNewswire-USNewswire/ -- Blood fluoride levels were significantly higher in patients with osteosarcoma than in control groups, according to research published in Biological Trace Element Research (April 2009).
First New Agent Approved to Treat Osteosarcoma in More Than 20 Years IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
IRVINE, Calif., Feb.
NASHVILLE, Tenn., Feb. 25 /PRNewswire/ -- After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients.
Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...
- a meat pie that is usually eaten at Christmas in Quebec